SCIEX’s ZenoTOF 8600 system acquired by Veloxity Labs
Veloxity Labs acquires SCIEX’s ZenoTOF 8600 system to accelerate peptide and complex bioanalysis.
Veloxity Labs (IL, USA) today announced the acquisition of the ZenoTOF 8600 system from SCIEX (MA, USA), making Veloxity the first bioanalytical CRO in the United States to acquire this new accurate mass spectrometer. This addition expands Veloxity’s toolkit for peptide and protein bioanalysis, strengthening method development speed, identity confirmation and interference resolution, while complementing its existing LC–MS/MS triple quadrupole platforms. Delivery of the system is expected later this year, with installation/qualification starting in January 2026.
The ZenoTOF 8600 system investment is a key part of Veloxity’s continued lab expansion, with expectations of adding an additional instrument lab, increased freezer storage and room for team growth later this year. This facility growth expands capacity and adds selectivity/sensitivity headroom for GLP-1 receptor agonists and broader peptide programs.
You may also be interested in:
- SCIEX announces new MS technologies and a biotech partnership
- Infographic: LC–MS analysis of oligonucleotides: a comprehensive guide
- Middle-down mass spectrometry: an interview with Roxana McCloskey
“Adding the ZenoTOF 8600 system gives our scientists a faster, more selective way to solve hard problems, especially in peptide and complex matrix workflows,” noted Shane Needham, CoFounder, President & CEO of Veloxity Labs. “We’re investing in innovation that will create an immediate impact on sponsor timelines: quicker method cycles, better tools to handle interferences and added sensitivity headroom for GLP-1 receptor agonists and other peptides. It’s a natural fit with our model of speed with purpose and our growth in capacity.”
What the ZenoTOF 8600 system brings to Sponsors:
- Peptide momentum (incl. GLP-1 RAs): HRAM selectivity/sensitivity and expanded mass range for intact peptides and proteins accelerate method setup and refinement, with headroom for low levels and small volumes.
- Confidence in complex matrices: Enhanced selectivity supports interference deconvolution and confirmation when biological matrices challenge traditional assays.
- Built to complement triple-quads: Routine regulated quantitative analysis stays efficient on triple-quads; the ZenoTOF 8600 system adds a problem-solving and selectivity path that can shorten overall development cycles for complex modalities.
- Continuity across phases: Methods and records are designed to carry forward efficiently, supporting an efficient transition from discovery to GLP and clinical with ICH M10-aligned practices.
Jose Castro-Perez, Vice President, Product Management at SCIEX, commented:
“We’re excited to support Veloxity’s early adoption of the ZenoTOF 8600 system. HRAM technology helps labs confirm identity, resolve challenging interferences and advance sensitive workflows — capabilities that matter for today’s peptide-rich pipelines. Veloxity’s focus on efficiency and scientific rigor makes them an ideal partner to showcase what the ZenoTOF 8600 system can unlock.”
